Carna Biosciences, Inc. (TYO:4572)

Market Cap	8.06B +66.8%
Revenue (ttm)	618.65M +3.3%
Net Income	-2.18B
EPS	-114.23
Shares Out	19.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	420,500
Average Volume	159,420
Open	478.00
Previous Close	470.00
Day's Range	418.00 - 479.00
52-Week Range	200.00 - 512.00
Beta	0.23
RSI	71.60
Earnings Date	May 8, 2026

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 61
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4572

Financial Performance

In 2025, Carna Biosciences's revenue was 579.00 million, a decrease of -8.96% compared to the previous year's 636.00 million. Losses were -2.17 billion, -0.32% less than in 2024.